The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group.
Bertram Glass
Honoraria - Roche
Research Funding - Astellas Pharma; Roche
Justin Hasenkamp
No relevant relationships to disclose
Gerald Wulf
Consultant or Advisory Role - Roche
Honoraria - Roche
Peter Dreger
No relevant relationships to disclose
Michael Pfreundschuh
Consultant or Advisory Role - Roche
Honoraria - Roche
Martin Gramatzki
No relevant relationships to disclose
Gerda Silling
No relevant relationships to disclose
Christian Wilhelm
No relevant relationships to disclose
Matthias Zeis
Honoraria - Roche
Sebastian Pfeiffer
No relevant relationships to disclose
Lorenz Trümper
Honoraria - Roche
Norbert Schmitz
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche